← Eichor
Condition: Neuroendocrine Carcinomas Nec Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Neuroendocrine Carcinomas Nec

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Phase 1/Phase 2 · 15 location(s) · Phanes Therapeutics · NCT05652686Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and
Phase 2 · 1 location(s) · Gustave Roussy, Cancer Campus, Grand Paris · NCT07016230A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma
Phase 1/Phase 2 · 25 location(s) · Nanjing Leads Biolabs Co.,Ltd · NCT06157827A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
Phase 1/Phase 2 · 13 location(s) · IDEAYA Biosciences · NCT07174583A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced
Phase 1 · 2 location(s) · Shanghai Henlius Biotech · NCT0741669518F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06503146FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum
Phase 2 · 31 location(s) · Centre Leon Berard · NCT06393816Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients
Phase 2 · 4 location(s) · Inkeun Park · NCT06893783ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
Phase 1/Phase 2 · 1 location(s) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd · NCT07038096SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Dif
Phase 1 · 1 location(s) · Peter Hosein, MD · NCT06889493A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Phase 1/Phase 2 · 6 location(s) · Tanabe Pharma America, Inc. · NCT06943521Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine Carcino
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07518602Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Sol
Phase 1/Phase 2 · 5 location(s) · Molecular Partners AG · NCT07278479A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06406465A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tu
Phase 1/Phase 2 · 26 location(s) · Crinetics Pharmaceuticals Inc. · NCT07129252Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Phase 1 · 7 location(s) · Novartis Pharmaceuticals · NCT07006727
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.